compared with the lowest quintile of acrylamide intake (mean intake: 9.5 microg/d), multivariable-adjusted hazard rates for renal cell, bladder, and prostate cancer in the highest quintile (mean intake: 40.8 microg/d) were 1.59 (95% ci: 1.09, 2.30; p for trend = 0.04), 0.91 (95% ci: 0.73, 1.15; p for trend = 0.60), and 1.06 (95% ci: 0.87, 1.30; p for trend = 0.69), respectively.